Citigroup Forecasts Strong Price Appreciation for Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock (NASDAQ:SRRK) had its price objective boosted by stock analysts at Citigroup from $55.00 to $58.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s price target suggests a potential upside of 25.68% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the company. Piper Sandler raised their price objective on Scholar Rock from $51.00 to $58.00 and gave the company an “overweight” rating in a research report on Wednesday. JPMorgan Chase & Co. increased their price target on shares of Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Finally, UBS Group initiated coverage on shares of Scholar Rock in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 target price for the company. Four investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $54.14.

Scholar Rock Stock Performance

Shares of SRRK stock opened at $46.15 on Wednesday. The firm has a market cap of $5.30 billion, a price-to-earnings ratio of -13.45 and a beta of 0.70. Scholar Rock has a 52-week low of $22.71 and a 52-week high of $49.82. The company has a quick ratio of 6.30, a current ratio of 6.95 and a debt-to-equity ratio of 0.41. The company’s 50 day moving average is $45.33 and its 200 day moving average is $39.19.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.10. During the same period in the prior year, the firm posted ($0.64) EPS. On average, sell-side analysts anticipate that Scholar Rock will post -2.42 EPS for the current fiscal year.

Insider Activity at Scholar Rock

In other Scholar Rock news, insider Caryn Parlavecchio sold 9,035 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $420,398.55. Following the transaction, the insider owned 169,087 shares in the company, valued at approximately $7,867,618.11. This represents a 5.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Mo Qatanani sold 8,484 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $47.07, for a total transaction of $399,341.88. Following the completion of the transaction, the insider directly owned 98,445 shares of the company’s stock, valued at approximately $4,633,806.15. This represents a 7.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 208,470 shares of company stock worth $9,201,778 in the last quarter. 13.30% of the stock is currently owned by company insiders.

Institutional Trading of Scholar Rock

Large investors have recently added to or reduced their stakes in the company. Orbis Allan Gray Ltd increased its holdings in shares of Scholar Rock by 1,034.5% in the fourth quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock valued at $151,044,000 after purchasing an additional 3,126,677 shares during the period. Wellington Management Group LLP boosted its position in Scholar Rock by 124.5% in the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock valued at $169,289,000 after buying an additional 2,521,022 shares during the last quarter. Holocene Advisors LP acquired a new position in Scholar Rock in the 3rd quarter worth approximately $91,670,000. Norges Bank acquired a new position in Scholar Rock in the 4th quarter worth approximately $91,603,000. Finally, Siren L.L.C. raised its position in Scholar Rock by 17.0% during the 4th quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock worth $476,842,000 after buying an additional 1,575,008 shares during the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Trending Headlines about Scholar Rock

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Major analysts raised ratings and targets — BMO bumped its target to $70 (Outperform), Citigroup raised its target to $58 (Buy) and Piper Sandler lifted its target to $58 (Overweight), signaling fresh upside expectations. Analyst Price Target Raises Piper Sandler Note
• Positive Sentiment: HC Wainwright raised its FY2030 EPS forecast to $1.26 (from $1.07) and reiterated a Buy rating with a $58 price target — a bullish long‑term earnings view that contrasts with current street estimates. HC Wainwright Upgrade
• Positive Sentiment: Scholar Rock reported progress on apitegromab: management outlined a 2026 BLA resubmission plan and commercial launch preparations following favorable interactions with the FDA — this is the primary operational catalyst for upside if approval and launch proceed. FDA / BLA Progress
• Neutral Sentiment: Q4 2025 results marginally beat expectations (EPS about -$0.88 vs. consensus ~ -$0.8825), showing stability but not a strong inflection in near‑term profitability. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Street consensus still expects a negative EPS for the current fiscal year (≈ -$2.42), underlining that near‑term earnings and cash‑flow risk remain until apitegromab is approved and commercialized. Consensus EPS Context

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).